ArticleToxicon: X2019
Can we resolve the taxonomic bias in spider venom research?
Article in Toxicon: X, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Vector venom: venomics of Aedes albopictus reveals a large enzyme repertoire and novel cecropins with activity against E. coli.npj drug discovery · 2026Article
- Comparative venomics suggests an evolutionary adaption of spider venom from predation to defense.Communications biology · 2025Article
- MultiStageSearch: An Iterative Workflow for Unbiased Taxonomic Analysis of Pathogens Using Proteogenomics.Journal of proteome research · 2025Article
- Spider venom potency exhibits phylogenetic prey specificity but does not trade-off with body size or silk use in prey capture.Biology letters · 2025Article
- Enlightening the toxinological dark matter of spider venom enzymes.npj biodiversity · 2024Article
- Venom Ex Machina? Exploring the Potential of Cell-Free Protein Production for Venom Biodiscovery.International journal of molecular sciences · 2024Article
- Determining the pharmacological potential and biological role of linear pseudoscorpion toxins via functional profiling.iScience · 2024Article
- Venom biotechnology: casting light on nature's deadliest weapons using synthetic biology.Frontiers in bioengineering and biotechnology · 2023Review
- Composition and toxicity of venom produced by araneophagous white-tailed spiders (Lamponidae: Lampona sp.).Scientific reports · 2022Article
- Article
- Venomics of the Central European Myrmicine AntsToxins · 2022Article
- Modern venomics-Current insights, novel methods, and future perspectives in biological and applied animal venom research.GigaScience · 2022Article
- A Spider Toxin Exemplifies the Promises and Pitfalls of Cell-Free Protein Production for Venom Biodiscovery.Toxins · 2021Article
- Morphological Analysis Reveals a Compartmentalized Duct in the Venom Apparatus of the Wasp Spider (Toxins · 2021Article
- An Economic Dilemma Between Molecular Weapon Systems May Explain an Arachno-atypical Venom in Wasp Spiders (Biomolecules · 2020Article
- Parallel Evolution of Complex Centipede Venoms Revealed by Comparative Proteotranscriptomic Analyses.Molecular biology and evolution · 2019Article
- Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rate of discovery of new spider species greatly exceeds the rate of spider venom characterisation, leading to an increasing number of species with unstudied venoms. However, recent advances in proteomics and genomics that enable the study of venoms from smaller species has expanded the accessible taxonomic range. Thus, although the number of unstudied spider venoms is likely to further increase, future research should focus on the characterisation of venoms and toxins from previously unstudied spider families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.